EUVIMEDEUVIMED entdecken
Crossref

Real-World Dupilumab Persistence in United States Children, Adolescents, and Adults With Atopic Dermatitis Over 24 Months

J Morel Symons, Janis L Breeze, Stevan G Severtson, Stefan Weiss, Dharm S Patel

Journal of Drugs in Dermatology · 2025

DOI: 10.36849/jdd.8931 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Drugs in Dermatology, 2025. Verfasst von J Morel Symons und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Dermatologic Agents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansAdolescentRetrospective StudiesUnited StatesMaleChildFemaleAdultYoung AdultTreatment OutcomeFollow-Up StudiesTime FactorsChild, PreschoolMiddle AgedSeverity of Illness Index

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedDermatologic Agents

Zitieren

APA

Symons, J. M., Breeze, J. L., Severtson, S. G., Weiss, S., & Patel, D. S. (2025). Real-World Dupilumab Persistence in United States Children, Adolescents, and Adults With Atopic Dermatitis Over 24 Months. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.8931

Vancouver

Symons JM, Breeze JL, Severtson SG, Weiss S, Patel DS. Real-World Dupilumab Persistence in United States Children, Adolescents, and Adults With Atopic Dermatitis Over 24 Months. Journal of Drugs in Dermatology. 2025. doi:10.36849/jdd.8931

BibTeX
@article{Symons2025,
  author = {Symons, J Morel and Breeze, Janis L and Severtson, Stevan G and Weiss, Stefan and Patel, Dharm S},
  title = {Real-World Dupilumab Persistence in United States Children, Adolescents, and Adults With Atopic Dermatitis Over 24 Months},
  journal = {Journal of Drugs in Dermatology},
  year = {2025},
  doi = {10.36849/jdd.8931}
}
Kostenlos starten →